<DOC>
	<DOCNO>NCT03054818</DOCNO>
	<brief_summary>This post-marketing drug safety monitoring study prospective manner , data collection perform registration-follow-up manner . Safety information patient receive intravitreal injection Conbercept Ophthalmic Injection medical institution involve study research actively monitor without intervene diagnosis treatment . All patient enrol follow one year .</brief_summary>
	<brief_title>Safety Evaluation China Patients : Long-term Treatment Outcome Conbercept Ophthalmic Injection Real Word（STONE）</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>1 . The condition inform consent freely give prior researchrelated procedure ; 2 . Patients receive least one intravitreal injection Conbercept Ophthalmic Injection inform consent give . 1 . Patients antiVEGF drug systematically locally , include limited bevacizumab , ranibizumab aflibercept , 90 day enrollment ; 2 . Those study drug study drug 30 informed consent give .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>